Centocor Diagnostics development of P-selectin heart attack test to be funded by IPO.
This article was originally published in The Gray Sheet
Executive Summary
CENTOCOR DIAGNOSTICS' DEVELOPMENT OF HEART ATTACK PREDICTION TEST would be funded by $20 mil. from a proposed initial public offering by the Centocor subsidiary. The P-selectin Profile test is designed to facilitate emergency room triage of patients suffering from acute coronary syndrome. Centocor is developing clinical lab assays and a point-of-care instrument to test for P-selectin.